SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
-------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 8, 2003
-------------
CYTOGEN CORPORATION
-------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-14879 222322400
--------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
650 College Road East, Suite 3100, Princeton, NJ 08540
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(609) 750-8200
---------------------------------
(Registrant's telephone number,
including area code)
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS.
On April 8, 2003, Cytogen Corporation (the "Company") announced the
amicable resolution of all open matters with Draximage Inc. ("Draximage"), the
radiopharmaceutical subsidiary of DRAXIS Health Inc., as well as the termination
of the Company's License and Distribution Agreement and Product Manufacturing
and Supply Agreement with Draximage, with respect to both of DRAXIS'
BrachySeed(TM) I-125 and BrachySeed(TM) Pd-103 products.
The Company and Draximage have also agreed to maintain the confidentiality
of each other's proprietary information, released each other from all other
liability with respect to any claims under such agreements, and agreed to
certain indemnification obligations with respect to third party claims.
Such press release is attached hereto as Exhibit 99.1, and is incorporated
herein by reference. The foregoing description of such press release is
qualified in its entirety by reference to such document.
Item 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND
EXHIBITS.
(c) Exhibits.
Exhibit No. Description
----------- -----------
99.1 Press release of the Company dated April 8, 2003
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Cytogen Corporation
By: /s/ Michael D. Becker
-----------------------------
Michael D. Becker,
President and Chief Executive Officer
Date: April 9, 2003